Graph not available
Graph not available

Open Demat Account

50years
50 Years
of Trust & Legacy
₹0 AMC
for First Year
₹0 Brokerage
on Delivery, Intraday, Currency and NSE F&O
left-arrow
Fundamentals
Financials
Shareholding
Resistance/Support
Delivery and Volume
About
Management
News
Similar Stocks
right-arrow

Vimta Labs Ltd Performance

Today's Low
481.10
arrowIcon
Today's High
501.80
52 Wk Low
365.80
arrowIcon
52 Wk High
623.15


Open

481.1

Traded Value (Cr)

55.34 L

Prev. Close

482.9

VWAP

487.7

Volume

11,498

Face Value

2

Vimta Labs Ltd Fundamentals

Market Cap
₹ 1,098 Cr
P/E Ratio (TTM)
26.58
P/B Ratio
3.70
Debt to Equity
0.07
ROE
13.97 %
EPS (TTM)
18.65
Dividend Yield
0.40%
Book Value
133.85

Click here to know more about Fundamentals

Vimta Labs Ltd Financials

Vimta Labs Ltd Financials

Vimta Labs Ltd Shareholding Pattern

Held By Mar 2024 Dec 2023 Sep 2023 Jun 2023
Promoters 36.92 % 36.98 % 37.01 % 37.23 %
Others 33.38 % 33.50 % 33.75 % 33.98 %
Retail 23.08 % 25.15 % 25.00 % 24.60 %
FII 5.13 % 2.88 % 2.74 % 2.72 %
Mutual Funds 1.49 % 1.49 % 1.49 % 1.48 %

Promoters

36.92%

Others

33.38%

Retail

23.08%

FII

5.13%

Mutual Funds

1.49%

Promoters

36.98%

Others

33.50%

Retail

25.15%

FII

2.88%

Mutual Funds

1.49%

Promoters

37.01%

Others

33.75%

Retail

25.00%

FII

2.74%

Mutual Funds

1.49%

Promoters

37.23%

Others

33.98%

Retail

24.60%

FII

2.72%

Mutual Funds

1.48%

Resistance and Support

₹500.05

PIVOT

resistance-arrow
Resistance
First Resistance₹510.450
Second Resistance₹525.350
Third Resistance₹535.750
support-arrow
Support
First Resistance₹485.150
Second Resistance₹474.750
Third Resistance₹459.850
RSI56.735
MACD24.481
ADX36.371
CCI-26.821

Delivery and Volume

PeriodDelivery Volume Traded Volume Delivery Volume %
Day11,4985,59948.70
Week23,82510,39043.85
1 Month73,79249,93349.73
6 Months26,44310,23938.72

About Vimta Labs Ltd

Vimta Labs Ltd., established in 1984, is India's most comprehensive contract research and testing organization, providing wide range of services to pharmaceutical, biopharmaceutical, food, consumer goods, electronic, electrical, agrochemical, healthcare, medical device and many other industries. Broadly, these services include: Drug discovery, development and drug life cycle management support services in the areas of preclinical research (GLP and non-GLP), clinical research, central lab, and cGMP as well as non-GMP analytical services for pharmaceutical and biopharmaceutical companies; Preclinical research and testing services for medical device companies; Contract research and testing for Agro-science companies; Food testing and analytical development services to support manufacturers, processors, farmers, retailers, traders, exporters, regulators; Clinical diagnostics services to patients, clinicians, hospitals and Environmental regulatory services such as impact assessments and post project monitoring, to industries such as infrastructure, power, cement, oil & gas, mining etc. The Company was awarded ISO 9002 Certification under ISO/IEC Guide-25 as Certified Competent Laboratory and Quality Endorsed Company by Standards Australia Quality Assurance Services Pty. Ltd in 1994. In 1997, the Company entered into a Joint Venture with Russian Centre for Testing and Certification, ROSTEST Moscow with an investment of 24% of the total Paidup Captial. The main essence of this Joint Venture was to diversify the activities in to preshipment inspection services for all Indian exports to Russia. During 2002, the company begun to offer Clinical Diagnostics Services. Clinical Specialty Diagnostics has been an internal requirement to screen the clinical trial subjects. Facilities were created in the year 2000 to speed up the clinical trials. The Company is now expanding its operations by five times of its existing capacities at S P Biotech Park, Genome Valley, Turkapally Village, Shamirpet Mandal, Ranga Reddy Dist. The project is expected to commence from September 2005. During the year 2006-07, the Analytical and Clinical Reference Lab facilities was shifted from the existing Cherlapally Facility to the newly established Life Sciences Facility in S.P.Biotech Park, Genome Valley, Hyderabad which started commercial operations from September, 2006. During the year 2020 Company acquired 100% Equity Shares of Emtac Laboratories Private Limited, on 04th March 2020, making Emtac a wholly owned subsidiary of the Company.

Managing Director

Harita Vasireddi

Founded

1990

NSE Symbol

VIMTALABS

Vimta Labs Ltd Management

NameDesignation
S P VasireddiExecutive Chairman
V HarrimanDirector (Operation)
Harita VasireddiManaging Director
Y Prameela RaniNon-Exec. & Independent Dir.
Sujani VasireddiCompany Sec. & Compli. Officer
G Purnachandra RaoNon-Exec. & Independent Dir.
Sanjay DaveNon-Exec. & Independent Dir.
Satya Sreenivas NeerukondaExecutive Director
Yadagiri R PendriNon-Exec. & Independent Dir.

Vimta Labs Ltd News

Vimta Labs to convene board meeting
On 18 May 2024
Vimta Labs to hold board meeting
On 30 March 2024
Vimta Labs climbs on securing Govt grant for upgrading lab
Vimta Labs rose 2.78% to Rs 525.25 after the company secured a grant of Rs 4.09 crore from the Ministry of Food Processing Industries (MoFPI) to upgrade its food testing laboratory.
Vimta Labs consolidated net profit declines 1.07% in the December 2023 quarter
Sales rise 5.56% to Rs 81.68 crore
Vimta Labs to conduct board meeting
On 31 January 2024
Vimta Labs allots 18,018 equity shares under ESOP
Vimta Labs consolidated net profit declines 52.08% in the September 2023 quarter
Sales decline 8.07% to Rs 73.41 crore
Vimta Labs to hold board meeting
On 30 October 2023
Vimta Labs consolidated net profit rises 1.33% in the June 2023 quarter
Sales rise 5.51% to Rs 83.49 crore
Vimta Labs to table results
On 28 July 2023

Similar Stocks

CompanyMarket CapMarket PriceP/E Ratio
CDSL₹ 21,652 Cr
₹ 2,072.00
(-4.46 %)
59.59
GODREJAGRO₹ 10,665 Cr
₹ 554.90
(-5.20 %)
29.87
RTNINDIA₹ 9,682 Cr
₹ 70.05
(-3.11 %)
20.25
THOMASCOOK₹ 9,378 Cr
₹ 199.30
(-4.85 %)
115.64
CMSINFO₹ 6,495 Cr
₹ 399.10
(-1.43 %)
20.31

Vimta Labs Ltd FAQ

By opening a demat account and having your KYC papers confirmed online, you may simply purchase Vimta Labs Ltd shares in BlinkX

The share price of any stock is volatile and changes during the day due to a variety of variables. Vimta Labs Ltd's share price is ₹491.80 as of May 10, 2024

Vimta Labs Ltd's P/E ratio is 26.58 times as of May 10, 2024.

Vimta Labs Ltd's most recent financial reports indicate a price-to-book ratio of 3.70, showing the company's stock market valuation in relation to the value of its real assets.

Market capitalisation, often known as market cap, is the market value of all outstanding shares of a publicly listed corporation. Vimta Labs Ltd's market is 1,099 Cr as on May 10, 2024.

The current financial records of Vimta Labs Ltd show a 13.97% ROE, showing great financial performance and effective capital utilisation, making it a significant statistic for investors.

The 52-week high/low price of a Vimta Labs Ltd stock is the highest and lowest price at which it has traded over that period (about one year) and is used as a technical indicator. Vimta Labs Ltd's 52-week high and low as of May 10, 2024 are ₹501.8 and ₹481.1 respectively.

As of the Mar 2024 quarter, the promoter shareholding in Vimta Labs Ltd stands at 36.92%. During the same period, Institutional Investors have shown a slight increase in their holdings, rising from 2.88% to 5.13%.